Clinical Trials Directory

An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Memantine

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- at least 18 years of age - suffering from OCD - Y-BOCS score of 18 or greater - taking a therapeutic dose of an anti-OCD medication specified in the protocol

External Links

Contact information

Primary Contact:

Nona Gamel 6507238601

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: